We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





In Vitro Confirmation of COVID-19 Drug Candidates Done Using AI-based Screening Technology

By HospiMedica International staff writers
Posted on 23 Apr 2020
Print article
Illustration
Illustration
SOM Biotech (Barcelona, Spain) has announced the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19. The three candidates inhibit the main protease of SARS-CoV-2 and therefore the replication of the virus. Clinical studies with the three candidates can be initiated immediately. SOM Biotech has applied its artificial intelligence-based screening technology (SOMAIPRO) to identify inhibitors of the 3CL proteases of SARS-CoV-2, SARS-CoV and MERS-CoV viruses as potential candidates to treat COVID-19. The discoveries came as a result of the research conducted jointly by SOM Biotech and the Department of Pharmacy and Pharmaceutical Sciences led by Professor Dong-Hae Shin from Ewha Womans University in South Korea.

Within the three identified and validated drug candidates, one – Eravacycline – is an already approved drug. The second compound – Prexasertib – is in clinical development and the third one – Cynarine – is a natural compound used as a dietary supplement. Therefore, all three drugs can be repurposed to treat COVID-19 and the company is working on the fastest way to prove them in patients. A patent application has been filed to provide a method of use protection for the three compounds worldwide.

“We have joined forces with Professor Dong-Hae Shin from Ewha Womans University to combine our scientific and medical expertise to find new therapies for the treatment of COVID-19,” said Raul Insa, CEO, and Founder of SOM Biotech. “Thanks to our capabilities in screening molecules with our AI-based technology, we have validated active anti-coronavirus compounds. Thus, we look forward to the rapid development of these drugs to be able to provide patients with an effective and safe treatment against the COVID-19 as soon as possible”.

“We are very proud about working on promising COVID-19 treatments and contributing to finding effective, safe and fast solutions due to the importance of the current pandemic situation,” said Professor Dong-Hae Shin from Ewha Womans University. “We decided to start working with SOM Biotech as we are committed to tackling this COVID-19 pandemic leveraging on partners with innovative technologies and excellent know-how.”

Related Links:
SOM Biotech

Gold Member
12-Channel ECG
CM1200B
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Medical Gas Blender
BlenderBuddy 1

Print article

Channels

Critical Care

view channel
Image: Researchers have developed an advanced shear-thinning hydrogel for aneurysm repair (Photo courtesy of TIBI)

New Hydrogel Features Enhanced Capabilities for Treating Aneurysms and Halting Progression

Aneurysms can develop in blood vessels in different body areas, often as a result of atherosclerosis, infections, inflammatory diseases, and other risk factors. These conditions lead to chronic inflammation,... Read more

Surgical Techniques

view channel
Image: The living replacement knee will be tested in clinical trials within five years (Photo courtesy of ARPA-H)

Living Knee Replacement to Revolutionize Osteoarthritis Treatment

Osteoarthritis is the most prevalent type of arthritis, characterized by the progressive deterioration of cartilage, or the protective tissue covering the bone ends, resulting in pain, stiffness, and impaired... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.